Quantitative Investigation of MicroRNA-32 in the Urine of Prostate Cancer Patients and Its Relationship With Clinicopathological Characteristics

Abstract

Introduction

Prostate cancer (PCa) is one of the most common cancers worldwide. PCa diagnosis is mostly based on solid biopsy and prostate-specific antigen (PSA), which have the disadvantages of being invasive and insensitive, respectively. Recently, the detection of microRNAs (miRNAs) in expressed prostatic secretions (EPS) has been a promising approach for PCa diagnosis. The aim of this study is to quantify transcriptional levels of miRNA-32 in the urine of prostate cancer patients.

Materials and methods

In this study, we evaluated the expression of miRNA-32 in the urine of 27 PCa patients, 48 benign prostatic hyperplasia (BPH) and 20 healthy controls, using quantitative real-time PCR (qPCR). The expression levels were then compared with the clinicopathological characteristics of patients.

Results

The expression level of miRNA-32 in PCa patients was significantly higher than the control group (P < .01) and BPH cases (P < .01), and was associated with advanced tumor stage (P < .05). In addition, the expression of miRNA-32 had significant correlation with patients’ age (r = 0.39, P = .043). Area under ROC curve (AUC) for the discrimination of PCa samples from control and BPH samples were 0.93 (P < .0001) and 0.78 (P < .0001), respectively. We also used logistic regression analysis to integrate the results of PSA, prostate volume and miRNA-32, and presented a predictive model for distinguishing PCa from BPH, highlighting the clinical utility of miRNA-32 in cancer diagnosis and risk assessment.

Conclusions

Measurement of miRNA-32 expression in urine may have significance for the detection of PCa. Inclusion of miRNA-32 in logistic regression along with PSA and prostate volume increases the accuracy of cancer diagnosis.